|Bid||0.000 x 0|
|Ask||0.000 x 0|
|Day's Range||32.060 - 32.115|
|52 Week Range||25.250 - 36.820|
|PE Ratio (TTM)||21.95|
|Dividend & Yield||1.03 (3.23%)|
|1y Target Est||N/A|
In 1H17, Novartis’s (NVS) subsidiary Sandoz reported revenues of around $4.9 billion, which is a 3% decline on a year-over-year (or YoY) basis.
In the first half of 2017, Roche’s (RHHBY) Ocrevus generated revenues of CHF 192.0 million.
Roche again disappointed this week with two studies on Tecentriq being put on partial hold while Pfizer's Bavencio received approval in Europe. TESARO's Zejula moved a step closer to approval.